Valuation: ARRD RESE

Market Cap 11.92B 10.37B 9.65B 8.86B 16.73B 1,138B 16.99B 114B 44.63B 567B 44.78B 43.8B 1,900B P/E 2026 *
-26.1x
P/E 2027 * -19.4x
Enterprise Value 10.95B 9.52B 8.86B 8.14B 15.36B 1,045B 15.6B 104B 40.99B 520B 41.13B 40.23B 1,745B EV / Sales 2026 *
25x
EV / Sales 2027 * 34.4x
Free-Float
94.54%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2007
Director of Finance/CFO - 13/05/2025
Chief Tech/Sci/R&D Officer - 01/08/2022
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 19/08/2010
Director/Board Member 66 19/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.13%-3.79%+34.48%+157.35% 25.98B
Weighted average by Cap. +0.23%-2.96%+28.67%+119.98%

Financials

2026 *2027 *
Net sales 439M 381M 355M 326M 616M 41.88B 625M 4.18B 1.64B 20.85B 1.65B 1.61B 69.92B 321M 279M 260M 238M 450M 30.63B 457M 3.06B 1.2B 15.25B 1.21B 1.18B 51.14B
Net income -463M -402M -375M -344M -649M -44.19B -660M -4.42B -1.73B -22B -1.74B -1.7B -73.77B -631M -548M -510M -469M -885M -60.21B -899M -6.02B -2.36B -29.97B -2.37B -2.32B -101B
Net Debt -972M -845M -786M -722M -1.36B -92.78B -1.38B -9.27B -3.64B -46.19B -3.65B -3.57B -155B -884M -768M -715M -657M -1.24B -84.38B -1.26B -8.43B -3.31B -42.01B -3.32B -3.25B -141B
Logo ARRD RESE
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-